Related references
Note: Only part of the references are listed.Efficacy and safety of eplerenone treatment for patients with diabetic nephropathy: A meta-analysis
Honglei Hu et al.
PLOS ONE (2022)
Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial
Niels H. Brandt-Jacobsen et al.
DIABETES & METABOLISM (2021)
Lowest nocturnal systolic blood pressure is related to heavy proteinuria and outcomes in elderly patients with chronic kidney disease
Xinru Guo et al.
SCIENTIFIC REPORTS (2021)
Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study
Johannes J. Kovarik et al.
DIABETES THERAPY (2021)
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Nina Vodosek Hojs et al.
PHARMACEUTICALS (2021)
Role of mineralocorticoid receptor antagonists in kidney diseases
Vishal Patel et al.
DRUG DEVELOPMENT RESEARCH (2021)
An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines
Nicholas M. Selby et al.
DIABETES OBESITY & METABOLISM (2020)
The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial
Hitoshi Minakuchi et al.
SCIENTIFIC REPORTS (2020)
A Prospective Single-Blind Randomized Trial of Ramipril, Eplerenone and Their Combination in Type 2 Diabetic Nephropathy
Mostafa El Mokadem et al.
CARDIORENAL MEDICINE (2020)
Effects of telmisartan on proteinuria and systolic blood pressure in dogs with chronic kidney disease
Yuichi Miyagawa et al.
RESEARCH IN VETERINARY SCIENCE (2020)
Hospitalizations among adults with chronic kidney disease in the United States: A cohort study
Sarah J. Schrauben et al.
PLOS MEDICINE (2020)
Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial
Joao Pedro Ferreira et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Efficacy and safety of mineralocorticoid receptor antagonists with ACEI/ARB treatment for diabetic nephropathy: A meta-analysis
Chao Zuo et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2019)
Antialbuminuric effect of eplerenone in comparison to thiazide diuretics in patients with hypertension
Toshiki Sawai et al.
JOURNAL OF CLINICAL HYPERTENSION (2017)
Low dose-eplerenone treatment decreases aortic stiffness in patients with resistant hypertension
Tatjana Kalizki et al.
JOURNAL OF CLINICAL HYPERTENSION (2017)
Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy
Li-Jing Sun et al.
JOURNAL OF DIABETES INVESTIGATION (2017)
Angiotensin II receptor blocker combined with eplerenone or hydrochlorothiazide for hypertensive patients with diabetes mellitus
Shigehiro Karashima et al.
CLINICAL AND EXPERIMENTAL HYPERTENSION (2016)
Add-On Use of Eplerenone Is Effective for Lowering Home and Ambulatory Blood Pressure in Drug-Resistant Hypertension
Kazuo Eguchi et al.
JOURNAL OF CLINICAL HYPERTENSION (2016)
Safety and Antihypertensive Effect of Selara (R) (Eplerenone): Results from a Postmarketing Surveillance in Japan
Shoko Takahashi et al.
INTERNATIONAL JOURNAL OF HYPERTENSION (2016)
Renoprotective effects of thiazides combined with loop diuretics in patients with type 2 diabetic kidney disease
Taro Hoshino et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2015)
Comparison of the Antialbuminuric Effects of Benidipine and Hydrochlorothiazide in Renin-Angiotensin System (RAS) Inhibitor-Treated Hypertensive Patients with Albuminuria: the COSMO-CKD (COmbination Strategy on Renal Function of Benidipine or Diuretics TreatMent with RAS inhibitOrs in a Chronic Kidney Disease Hypertensive Population) Study
Katsuyuki Ando et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2014)
Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function Analyses of the EMPHASIS-HF Study Subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)
Romain Eschalier et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Eplerenone Attenuates Pulse Wave Reflection in Chronic Kidney Disease Stage 3-4-A Randomized Controlled Study
Lene Boesby et al.
PLOS ONE (2013)
Safety of enhanced renin-angiotensin-aldosterone system inhibition with aliskiren in nondiabetic patients with chronic kidney disease
Slawomir Lizakowski et al.
POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE (2013)
The Enhanced Renin-Angiotensin-Aldosteron System Pharmacological Blockade - Which is the Best?
Leszek Tylicki et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2012)
Moderate Antiproteinuric Effect of Add-On Aldosterone Blockade with Eplerenone in Non-Diabetic Chronic Kidney Disease. A Randomized Cross-Over Study
Lene Boesby et al.
PLOS ONE (2011)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus
Hylton V. Joffe et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension
GH Williams et al.
AMERICAN JOURNAL OF CARDIOLOGY (2004)
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL
D de Zeeuw et al.
KIDNEY INTERNATIONAL (2004)